2026/11/11
Kind of a big deal? For anyone who has ever counted the days after surgery, we think so.
At BIO-Europe 2026 in Cologne, our CEO George Yeh shared the positive Phase 3 results for TLC590, our investigational long-acting medicine for pain after surgery. In the trial, a single dose gave pain relief lasting seven days, and patients needed less rescue opioid medication.
He also presented TLC599, designed to ease knee osteoarthritis pain for up to 24 weeks with one injection.
Thank you to everyone who came to listen. We’re looking for partners to help bring both medicines to the people waiting for them.
「Kind of a BIG DEAL」。對每一位數著日子等傷口不痛的病人來說,這真的是大事。
TLC 執行長葉志鴻在德國科隆 BIO-Europe 2026 登台,分享 TLC590 第三期臨床試驗的正面結果。TLC590 是我們開發中的長效術後止痛藥物,試驗中單次給藥的止痛效果可持續七天,病人使用的救援性鴉片類止痛藥也較少。
他同時介紹了 TLC599:一針可望緩解退化性膝關節炎疼痛長達 24 週。
謝謝每一位到場聆聽的朋友。我們正在尋找合作夥伴,一起把這兩項藥物帶給等待的病人。
#術後疼痛 #退化性關節炎 #生技